Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Electro-Optical completes MelaFind trial

This article was originally published in Clinica

Executive Summary

Electro-Optical Sciences (EOS), of Irvington, New York, has completed its pivotal trial of MelaFind, its melanoma detection device. MelaFind was used to evaluate over 1,800 suspicious skin lesions from over 1,300 patients. All the lesions deemed "suspicious" by the system were subsequently biopsied and sent for dermatohistopathologic analysis. Results are anticipated in the fourth quarter of 2008, with a PMA application to the US FDA to follow. The noninvasive, hand-held imaging system emits multiple wavelengths of light to obtain data on suspicious pigmented skin lesions up to 2.5mm deep. It analyses these data using proprietary algorithms to compare them with a database of melanomas and benign lesions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel